Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

by Ohe, Yuichiro , Rosen, Ezra , Kim, Yu-Jung , Ebata, Kevin , Nair, Binoj , Peled, Nir , Pennell, Nathan A , Sakamoto, Tomohiro , Cho, Byoung C , Johnson, Melissa , Gautschi, Oliver , Cassier, Philippe A , Besse, Benjamin , Park, Keunchil , Rothenberg, S. Michael , Patel, Jyoti , Subbiah, Vivek , Ohashi, Kadoaki , Nishio, Makoto , Olek, Elizabeth , Gainor, Justin , Shah, Manisha H , Zhu, Edward Y , Velcheti, Vamsidhar , Seto, Takashi , Weiss, Jared , De Braud, Filippo , Reckamp, Karen L , Wolf, Jürgen , McCoach, Caroline E , Drilon, Alexander , Oxnard, Geoffrey R , Garralda, Elena , Bazhenova, Lyudmila , Nguyen, Michele , Huang, Xin , Barlesi, Fabrice , Satouchi, Miyako , Goto, Koichi , Loong, Herbert H.F , Solomon, Benjamin , Yang, Luxi , Dy, Grace K , Tan, Daniel S.W , Falchook, Gerald

in Adult / Aged / Aged, 80 and over / Alanine / Alanine transaminase / Aspartate aminotransferase / Carcinoma, Non-Small-Cell Lung - drug therapy / Cell fusion / Central nervous system / Chemotherapy / Collaboration / Drug dosages / Female / Humans / Hypertension - chemically induced / Hyponatremia / Intention to Treat Analysis / Kinases / Lung cancer / Lung Neoplasms - drug therapy / Lymphopenia / Male / Medical imaging / Metastases / Metastasis / Middle Aged / Mutation / Non-small cell lung carcinoma / Oncology / Pharmacokinetics / Platinum / Progression-Free Survival / Protein Kinase Inhibitors - administration & dosage / Protein Kinase Inhibitors - adverse effects / Proto-Oncogene Proteins c-ret - analysis / Proto-Oncogene Proteins c-ret - antagonists & inhibitors / Proto-Oncogene Proteins c-ret - genetics / Pyrazoles - administration & dosage / Pyrazoles - adverse effects / Pyridines - administration & dosage / Pyridines - adverse effects / Small cell lung carcinoma / Statistical analysis / Transaminases - blood / Treatment Outcome / Young Adult

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

2020

Confirm

Do you wish to request the book?

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Ohe, Yuichiro,

Rosen, Ezra,

Kim, Yu-Jung,

Ebata, Kevin,

Nair, Binoj,

Peled, Nir,

Pennell, Nathan A,

Sakamoto, Tomohiro,

Cho, Byoung C,

Johnson, Melissa,

Gautschi, Oliver,

Cassier, Philippe A,

Besse, Benjamin,

Park, Keunchil,

Rothenberg, S. Michael,

Patel, Jyoti,

Subbiah, Vivek,

Ohashi, Kadoaki,

Nishio, Makoto,

Olek, Elizabeth,

Gainor, Justin,

Shah, Manisha H,

Zhu, Edward Y,

Velcheti, Vamsidhar,

Seto, Takashi,

Weiss, Jared,

De Braud, Filippo,

Reckamp, Karen L,

Wolf, Jürgen,

McCoach, Caroline E,

Drilon, Alexander,

Oxnard, Geoffrey R,

Garralda, Elena,

Bazhenova, Lyudmila,

Nguyen, Michele,

Huang, Xin,

Barlesi, Fabrice,

Satouchi, Miyako,

Goto, Koichi,

Loong, Herbert H.F,

Solomon, Benjamin,

Yang, Luxi,

Dy, Grace K,

Tan, Daniel S.W,

Falchook, Gerald

2020

Overview

RET fusion–positive lung cancer accounts for 1 to 2% of non–small-cell lung cancers. Among previously treated patients with RET fusion–positive lung cancer, 64% of those who received selpercatinib, a RET kinase inhibitor, had a response, and among previously untreated patients, 85% had a response. Approximately one third of the patients had adverse events of grade 3 or higher.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Alanine

/ Alanine transaminase

/ Aspartate aminotransferase

/ Carcinoma, Non-Small-Cell Lung - drug therapy